A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma

BACKGROUND: Sunitinib is a multi‐target tyrosine kinase inhibitor (TKI) that inhibits VEGF receptor 1, 2, 3 (VEGFRs), platelet‐derived growth factor receptor (PDGFR), colony‐stimulating factor receptor (CSFR), and the stem cell factor receptor c‐KIT. Temsirolimus inhibits mammalian target of rapamyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ness, Dylan B., Pooler, Darcy B., Ades, Steven, Highhouse, Brian J., Labrie, Bridget M., Zhou, Jie, Gui, Jiang, Lewis, Lionel D., Ernstoff, Marc S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315788/
https://www.ncbi.nlm.nih.gov/pubmed/37148554
http://dx.doi.org/10.1002/cam4.5990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315788/
https://www.ncbi.nlm.nih.gov/pubmed/37148554
http://dx.doi.org/10.1002/cam4.5990

Ejemplares similares